Sionna Therapeutics, Inc. (SION) Stock Analysis & Investment Frameworks

Sionna Therapeutics, Inc. (SION) stock analysis on Invetso. Review Sionna Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Sionna Therapeutics, Inc. Company Overview

Sionna Therapeutics, Inc. Key Financial Metrics

About Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Sionna Therapeutics, Inc. Investment Frameworks

Invetso analyzes Sionna Therapeutics, Inc. (SION) across the following frameworks:

Explore More SION Research